Loading news...
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –
Arvinas (NASDAQ: ARVN) executives outlined a portfolio shift toward early-stage development and previewed multiple clinical catalysts in a discussion hosted by Barclays biotech analyst Esra Darroudi. Chief Executive Officer Randy Teel and Chief Scientific Officer Angela Cacace said the company is entering 2026 with four Phase 1 programs and expects clinical data for three of those
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for presentations in 2026 – – Phase 1 trial in healthy volunteers initiated with polyQ-AR degrader ARV-027; first immuno-oncology PROTAC HPK1 degrader, ARV-6723, on track to initiate Phase 1 trial in mid-2026 – – Randy Teel, Ph.D., appointed President, Chief Executive Officer, and Director – – Company to host conference call today at 8:00 a.m.
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here , at 1:10 p.m.
BML Capital Management LLC bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $426,000. Arvinas comprises about 0.3% of BML Capital Management
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET.
Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 4,262,275 shares, a drop of 15.6% from the January 15th total of 5,052,067 shares. Currently, 7.0% of the shares of the company are sold
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D.
Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) has been assigned an average rating of "Hold" from the twenty-two brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating on the company. The
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) traded down 2.6% during mid-day trading on Monday. The company traded as low as $11.01 and last traded at $11.17. 684,941 shares traded hands during trading, a decline of 15% from the average session volume of 807,178 shares. The stock had previously closed at $11.47.
Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) in the undefined quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company's stock, valued at approximately $2,194,000. Caxton Associates LLP owned 0.41% of Arvinas at the end of the most recent
Shares of Arvinas, Inc. (NASDAQ: ARVN - Get Free Report) have been assigned an average rating of "Hold" from the twenty-three research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN, Conn., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody, presented in a poster at the 67th American Society of Hematology (ASH®) Annual Meeting and Exposition, held December 6–9, 2025, in Orlando, Florida.
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is being developed with Pfizer Inc. (NYSE: PFE) as a potential monotherapy for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting.* Ongoing studies are also evaluating vepdegestrant as a monotherapy and as part of combination therapy for ER+/HER2- breast cancer.
Campbell and CO Investment Adviser LLC acquired a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 54,832 shares of the company's stock, valued at approximately $404,000. Campbell and CO Investment Adviser LLC